Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy-Reference-Cited by-同舟云学术

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

Published:2013-01-16 Issue:1 Volume:15 Page:
ISSN:1532-429X
Container-title:Journal of Cardiovascular Magnetic Resonance
language:en
Short-container-title:J Cardiovasc Magn Reson

Author:

Pepe Alessia,Meloni Antonella,Rossi Giuseppe,Cuccia Liana,D’Ascola Giuseppe Domenico,Santodirocco Michele,Cianciulli Paolo,Caruso Vincenzo,Romeo Maria Antonietta,Filosa Aldo,Pitrolo Lorella,Putti Maria Caterina,Peluso Angelo,Campisi Saveria,Missere Massimiliano,Midiri Massimo,Gulino Letizia,Positano Vincenzo,Lombardi Massimo,Ricchi Paolo

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology

Link

http://link.springer.com/content/pdf/10.1186/1532-429X-15-1.pdf

Reference31 articles.

1. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A: Cardiac morbidity and mortality in Deferoxamine- or Deferiprone-treated patients with thalassemia major. Blood. 2006, 107: 3733-3737. 10.1182/blood-2005-07-2933.

2. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, et al: Randomized controlled trial of Deferiprone or Deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006, 107: 3738-3744. 10.1182/blood-2005-07-2948.

3. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, de Marchi D, Midiri M, Maggio A: Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006, 76: 183-192. 10.1111/j.1600-0609.2005.00587.x.

4. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ: A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with Deferoxamine and Deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007, 115: 1876-1884. 10.1161/CIRCULATIONAHA.106.648790.

5. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ: Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008, 10: 12-10.1186/1532-429X-10-12.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A hybrid framework based on knowledge distillation for explainable disease diagnosis;Expert Systems with Applications;2024-03

2. Pancreatic iron in pediatric transfusion‐dependent beta‐thalassemia patients: A longitudinal MRI study;Pediatric Blood & Cancer;2024-02-22

3. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy;BLOOD TRANSFUS-ITALY;2024

4. A Case of Children <i>β</i>-Thalassemia Major Complicated with Liver Cirrhosis and Literature Review;Advances in Clinical Medicine;2024

5. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia;Cochrane Database of Systematic Reviews;2023-11-17